Abstract
Background Increased rates of TE have been reported in patients with coronavirus disease (COVID-19), even without prior predisposition to thrombosis. Cancer patients are already predisposed to a hypercoagulable state. We aimed to assess whether COVID-19 further increased the risk of thromboembolism (TE) in patients with active cancer.
Methods Data from cancer patients with documented COVID-19 were retrospectively reviewed up to April 10th, 2020. Active cancer was defined as disease treated within the past year. Patients' work-up of thrombosis was done at the clinicians' discretion. All imaging studies' reports within 30 days of the COVID-19 positive test were reviewed for identification of new arterial and/or venous TE. Patients were followed for 30 days from the date of COVID-19+ test for development of TE, hospital length of stay (LOS) and mortality.
Results Of 90 patients, eleven (12.2%) were found to have 13 new TE within 30 days of COVID-19+ test: 8 (8.9%) arterial and 5 (5.6%) venous. Arterial TE were primarily new strokes and/or microvascular cerebral disease (7) with 1 splenic infarct. Venous TE were superficial (1) and deep (3) venous thromboses with 1 pulmonary embolism. Peak D-dimer (DD) values were numerically higher in the TE group vs those with no TE, median peak DD, 7.7 vs 3.2, p=0.25. Out of the patients with CKD/ESRD, 72.7% developed TE vs 31.6% of the those without kidney disease, p=0.02. Hospitalized patients on either prophylactic or therapeutic anticoagulation (AC) had fewer TE than those patients who received no anticoagulation: 9.1% vs 79.0%, p<0.0001. Only 1 patient on enoxaparin prophylaxis developed TE. Mortality was higher in the TE group with a HR of 2.6 for TE vs no TE 95% CI (1.2 - 5.6), p=0.009. Cancer type, disease stage (metastatic vs non), administration of prior chemotherapy, patient setting (inpatient, ICU, outpatient, ED visit), LOS and ventilation did not correlate with increased incidence of TE.
Conclusion Patients with COVID-19 have increased rates of TE, which remained consistent in patients with active cancer within our population. Interestingly, a high incidence of arterial events was noted. TE was associated with worse survival outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
These studies were supported by Albert Einstein Cancer Center Grant (P30CA013330).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Montefiore- Einstein Institutional Review Board (IRB) reviewed and approved the study and waived the need for informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Subgroup analysis was conducted.
Data Availability
The data were extracted from Montefiore Healthcare System EMR.
